Endovia Health Sciences, Inc. (NYSE:EDVA) ("Endovia" or the "Company"), an emerging cannabinoid-based health sciences company, today welcomed recent developments in the federal marijuana rescheduling process, including the position advanced by the federal government during the Drug Enforcement Administration’s ("DEA") recent administrative hearings supporting the proposed transfer of marijuana from Schedule I to Schedule III of the Controlled Substances Act.

The Company believes the federal government’s affirmative support for Schedule III represents a significant evolution in U.S. cannabinoid policy and provides an increasingly clear signal that the federal government is moving toward a long-term regulatory framework that recognizes the medical potential of cannabinoids while maintaining appropriate federal oversight.